Exogenous ketone ester

Phase 3Small molecule

SSohag University

Exogenous ketone ester is one of 48 small molecule programs targeting Epilepsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpilepsyRecruiting

EpilepticsRecruiting

EpilepsyPhase 3

Recruiting

EpilepticsPhase 3

Recruiting

Competition

Competitive Landscape

84 competitors in Epilepsy

#DrugCompanyPhaseTrials

Vimpat

UCB

Approved

11 2

Fycompa

CCatalyst Biosciences

Approved

14 3

Diamox

Briviact

15 5

Zoloft

VViatris Specialty LLC

Approved

2 6

Ketalar

AAultman Health Foundation

Approved

1 7

Versed

CConrado Roberto Hoffmann Filho

Coreg

Glucophage

Advil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epilepsy1 trial

Exogenous Ketone Esters for Drug Resistant Epilepsy

Recruiting·SSohag University·Phase 2/3·NCT05670847·60 enrolled

Epileptics1 trial

Exogenous Ketone Esters for Refractory Status Epileptics

Recruiting·SSohag University·Phase 2/3·NCT05674552·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Exogenous ketone ester. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exogenous ketone ester compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exogenous ketone ester. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSohag University

Exogenous ketone ester

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epilepsy1 trial

Epileptics1 trial

References

Drug Info

Quick Facts

Related News